Classroom Study of SPN-812 in Children With ADHD
Researchers are comparing 200 mg SPN-812 and placebo, tracking side effects to assess safety in children with ADHD.
Understand this study
What is this study about?
Researchers are comparing 200 mg SPN-812 and placebo, tracking side effects to assess safety in children with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria apply.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 6 Years to 11 Years
- Official registry ID
- NCT04016792
- Official title
Show the full official title
An Analog Classroom Study: Efficacy and Safety of SPN-812 in Children With Attention-Deficit/Hyperactivity Disorder
Recruitment & locations
Locations not listed
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing 200 mg SPN-812 and placebo, tracking side effects to assess safety in children with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Placebo and 200 mg SPN-812.
Who can participate?
This study is for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
